Sage Therapeutics (SAGE) Posts Q2 Loss of $4.57/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to Sage Therapeutics (SAGE) Posts Q2 Loss of $4.57/Share
August 12, 2014 7:46 AM EDT
Leerink Swann initiated coverage on Sage Therapeutics (NASDAQ: SAGE) with an Outperform rating and a price target of $46.00.
For an analyst ratings summary and ratings history on Sage Therapeutics click here. For more ratings news on Sage Therapeutics click here.
Shares of Sage Therapeutics closed at $33.40 yesterday.
...
More
August 12, 2014 7:45 AM EDT
(Updated - August 12, 2014 11:16 AM EDT)
Canaccord Genuity initiated coverage on Sage Therapeutics (NASDAQ: SAGE) with a Buy rating and a price target of $40.00.
Analyst John Newman said, "We are initiating coverage on SAGE Therapeutics... More
August 12, 2014 7:45 AM EDT
JPMorgan initiated coverage on Sage Therapeutics (NASDAQ: SAGE) with an Overweight rating and a price target of $42.00.
For an analyst ratings summary and ratings history on Sage Therapeutics click here. For more ratings news on Sage Therapeutics click here.
Shares of Sage Therapeutics closed at $33.40 yesterday.
...
More
August 12, 2014 7:44 AM EDT
Goldman Sachs initiated coverage on Sage Therapeutics (NASDAQ: SAGE) with a Neutral rating and a price target of $38.00.
Analyst Navdeep Singh said, "Sage is a small-cap biotech focused on developing drugs for central nervous... More
